Abstract
Several variants of concern (VOCs) explain most of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) epidemic waves in Europe. We aimed to dissect the spread of the SARS-CoV-2 VOCs in the Canary Islands (Spain) between December 2020 and September 2021 at a micro-geographical level. We sequenced the viral genome of 8,224 respiratory samples collected in the archipelago. We observed that Alpha (B.1.1.7) and Delta (B.1.617.2 and sub-lineages) were ubiquitously present in the islands, while Beta (B.1.351) and Gamma (P.1/P.1.1) had a heterogeneous distribution and were responsible for fewer and more controlled outbreaks. This work represents the largest effort for viral genomic surveillance in the Canary Islands so far, helping the public health bodies in decision-making throughout the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by Cabildo Insular de Tenerife [grants CGIEU0000219140 and Apuestas cientificas del ITER para colaborar en la lucha contra la COVID-19]; the agreement with Instituto Tecnologico y de Energias Renovables (ITER) to strengthen scientific and technological education, training research, development and innovation in Genomics, Personalized Medicine and Biotechnology [grant number OA17/008]; Ministerio de Ciencia e Innovacion [grant number RTC-2017-6471-1], co-funded by the European Regional Development Fund (ERDF). The funders had no role in the study design, collection, analysis and interpretation of data, in the writing of the manuscript or in the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University Hospital Nuestra Señora de Candelaria (Santa Cruz de Tenerife, Spain) review board approved the study (ethics approval number: CHUNSC_2020_24).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Co-first authorship
cflores{at}ull.edu.es, lciuffreda.bio{at}gmail.com, hector.rodriguez.11{at}ull.edu.es
rgonzalezmontelongo{at}iter.es, ainigo{at}iter.es, jlorsal{at}gmail.com, cflores{at}ull.edu.es
juliaalcoba{at}gmail.com, diegogarciamartinezdeartola{at}gmail.com, helegc{at}hotmail.com, odiegil{at}gobiernodecanarias.org
imigmar{at}gobiernodecanarias.org, ttosnun{at}gobiernodecanarias.org
avalenzu{at}ull.edu.es
Data Availability
All data produced in the present study are available at GISAID.
